Biogen is cutting a billion-dollar check for San Diego immunology startup RayThera, a deal announced yesterday that folds early-stage small-molecule anti-inflammatory programs into the Cambridge drugmaker’s pipeline. The buyout is timed to hustle RayThera’s lead candidate into first‑in‑human testing, with the program expected to enter Phase 1 in the early third quarter of 2026. It is the latest in a growing line of big drugmakers scooping up well‑funded local teams as they bulk up in immunology.
As reported by the Boston Business Journal, Biogen, headquartered in Kendall Square, agreed to pay up to $1 billion for the San Diego startup in a mix of upfront cash and contingent milestone payouts tied to clinical and regulatory milestones. The outlet notes that the deal zeroes in on early‑stage therapies for immune‑mediated conditions, giving Biogen another angle into a hot corner of drug development.
Deal Terms and Timeline
According to Reuters, the transaction structure combines an initial cash payment with additional milestone‑based payouts, and RayThera’s lead program is slated to enter Phase 1 in the early third quarter of 2026. Reuters also points out that the agreement lands in the middle of a busy year for biotech dealmaking, as larger pharmaceutical players keep hunting for promising immunology assets rather than building everything in‑house.
RayThera's Funding and Science
RayThera raised $110 million in a Series A round co‑led by Foresite Capital and OrbiMed in April 2025, according to Business Wire. The San Diego outfit lists its offices at 11988 El Camino Real, Suite 600, and describes itself as a small‑molecule immunology developer on its RayThera website.
Biogen's M&A Push
The RayThera deal follows Biogen’s larger acquisition of Apellis Pharmaceuticals, which Biogen completed on May 14, adding commercial products and a nephrology footprint, according to Biogen. Taken together, the two deals underscore a strategic effort to broaden Biogen’s growth engines beyond its traditional neurology focus and lean harder into immunology and related areas.
What It Means for San Diego
For San Diego’s life‑science community, the sale marks another notable exit for a venture‑backed team and investors who bet on small‑molecule immunology. Investors named in RayThera’s Series A, including Foresite Capital and OrbiMed, are listed in earlier press filings and highlight continued venture interest in the region’s immunology talent pool.
The companies said the transaction is subject to customary closing conditions and that financial terms include upfront and contingent milestone payments. Observers will be watching for formal filings and any added detail on integration plans as the deal moves through the usual corporate and regulatory checkpoints, according to Reuters.
